Latest News

Announcing ATTi 2020

ScitoVation, with support of long-time research partners, is pleased to announce the Advancement of Transcriptomics for Toxicology initiative, or ATTi. Read more »


Development and Application of a Life Stage Physiologically based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans

While insecticides are an essential to many food supply and public health concerns, they are sometimes associated with bioactivity and therefore raise questions about human and environmental health implications. Pyrethroids are insecticides used in household products, agricultural applications and mosquito control. In rat, juveniles were
more sensitive than adults to pyrethroid-driven health effects. The US Environmental Protection Agency (USEPA) raised questions about …Read more »


Upcoming Webinar

On Thursday, May 27th, 2020 at 11:00 AM Eastern Standard Time, join ScitoVation, L.L.C. experts in kinetic modeling and IONTOX, L.L.C. known for in vitro toxicity testing for a 45 minute webinar describing the integrated organ platform and the use of kinetic modeling. During the webinar James McKim, Ph.D. DABT will present first on the IONTOX HuDMOP™ integrated organ platform and data generated followed by Melvin Andersen, Ph.D., DABT who will discuss models that describe chemical behavior. Following the formal presentation there will be a 15 minute Q&A session. A recording of the live webinar will be made available to all who register prior to webinar. Attendance is limited to the first 150 registrants. Read more »


Mel’s Blog: Differential Gene Expression Analysis at ScitoVation

Differential gene expression analysis (DGEA) in tissues from exposed animals or in treated cells helps define the biological targets of chemicals, that is, their molecular initiating events (MIEs), and the manner in which the compounds cause effects, their modes- of-action (MOA). Understanding MIEs and MOAs helps ScitoVation clients and sponsors to use appropriate risk assessment methods for higher volume chemicals and to gauge the safety of the much larger number of compounds that have more limited toxicity information…Read more »


Message From Jean Orelien (CEO): ScitoVation Response to COVID-19 Pandemic

Dear Friends & Colleagues,

During this unprecedented global health crisis, ScitoVation would like to send its heartfelt gratitude to all of you on the front lines of the COVID-19 pandemic that continue tirelessly to serve your communities. Medical doctors, nurses, researchers, public servants, elected officials, emergency workers, store clerks, police, grocers, food service workers, National Guard troops, and military personnel, and all other dedicated professionals and volunteers are all performing vital functions in this torrid time and we thank you for your service to our communities and our safety.
Read more »


A Comparison of Cell Culture Models and Exposure Routes for In Vitro Inhalation Toxicity Testing

Development of in vitro assays for point-of-contact inhalation toxicity should consider two factors: 1) the physiological relevance of the cell culture model, and 2) the route of exposure. Organotypic culture models may better replicate in vivo adverse outcomes and allow for repeat exposures, whereas simpler cell-line-based models may be more applicable to high-throughput acute testing. Exposure of submerged cultures to compounds in solution is a commonplace approach, compatible with many in vitro assays and amenable to scaling for high-throughput testing. However, exposure of cultures at the air-liquid interface may better simulate in vivo inhalation exposure to vapors…Read more »


ScitoVation and BioPredic International Announce Partnership for HepaRG® Contract Service & Research in the Americas

Durham, N.C., USA March 23rd, 2020 — ScitoVation, a solution leader recognized as industry experts in cell-based assays and computational methods announced today the launch of a partnership with BioPredic International, a contract services, research and life sciences tools provider based in France. The partnership centers around the Biopredic-owned HepaRG® immortal liver cell line. ScitoVation will serve as a center of service excellence in the Americas for HepaRG® as BioPredic’s preferred CRO partner in the Americas providing contract services, product development and technical support to the market. Together the two companies will launch …Read more »


Developing Toxicity and Pharmacokinetic Models for an in vitro Integrated Organ Platform (HuDMOP™)

In vitro methods capable of describing systemic effects of chemicals require use of multiple tissue types connected with a common perfusate. This arrangement allows integration of absorption, metabolism and toxicity data over extended times in vitro and provides a novel, animal-free tool for chemical, cosmetic, and pharmaceutical testing. In order to test this, a study on the uptake and distribution of acetaminophen (APAP) in a human dynamic multi-organ plate (HuDMOP™) with three tissue surrogates arranged in series: first…Read more »